China’s growth continues as country becomes clinical trial powerhouse
As China’s powerhouse status grows even bigger in the clinical trial space, industry leaders are set to come together to…
All articles by Abigail Beaney
Abigail Beaney
Abigail Beaney is the editor of Clinical Trials Arena. Abigail has expertise in clinical trial regulation, trial design, outsourcing, and cell and gene therapies. Abigail also has covered news and has a wealth of knowledge across several therapy areas including neurodegenerative, infectious and metabolic diseases. Abigail holds a first-class BA (Hons) degree in Journalism from the University of Central Lancashire in the United Kingdom. She has also obtained the National Qualification in Journalism through the UK's media industry body, the National Council for the Training of Journalists. Contact Abigail
-
-
BioVie stock sinks on Phase IIb Parkinson’s trial data
BioVie’s stock crashed after the biotech released data from its Phase IIb Parkinson’s disease trial that used a unique composite…
-
Moderna kicks off Phase I Ebola trial as Africa readies itself for research
Moderna has initiated a Phase I trial of its mRNA Ebola vaccine for the Bundibugyo variant, just as Africa is…
-
UK Prime Minister to meet with brain cancer patient after research appeal
The UK's Prime Minister, Andy Burnham, has agreed to meet with a Team GB swimmer who suffers from brain cancer…
-
Otsuka’s Voyxact stabilised kidney function at two years in Phase III IgAN trial
Otsuka Pharmaceutical’s Voyxact (sibeprenlimab-szsi) stabilised kidney function for over two years in patients with primary IgA nephropathy (IgAN) at risk…
-
Schizophrenia “non-responders” may need more time, study finds
A research study has indicated that researchers should better consider time differences between individual symptom improvement during schizophrenia clinical trials.…
-
High Court gives go-ahead for UK puberty blocker trial to continue
The UK’s High Court has rejected a challenge to the regulatory approval for a clinical trial that is investigating puberty…
-
Novo Nordisk’s mAb for MACE risk reduction fails in Phase III trial
Novo Nordisk’s monoclonal antibody (mAb) designed to reduce the risk of major adverse cardiovascular events (MACE) in patients with atherosclerotic…
-
Pfizer seeks label expansion for Litfulo after double Phase III NSV win
Pfizer’s Litfulo (ritlecitinib) could be set for a label expansion after it met the endpoints of two Phase III studies…
-
ViiV’s two-monthly HIV jab bests daily oral drugs in African teenagers
ViiV Healthcare’s two-monthly HIV drug has demonstrated superiority over daily oral medication in a Phase III trial conducted in four…